16 production sites on 5 continents.
Affiliates or offices in 79 countries.
Products marketed in more than 170 countries.
Approximately 42,700 employees (FTEs March 2018).
19% within research and development
32% in production and production administration
37% in international sales and marketing
12% in administration
Affiliate distribution (FTEs)
Approximately 41% of employees are located in Denmark (17,294 FTEs) and 59% in the rest of the world:
Africa, Asia, Middle East & Oceania: 6,858
Europe (excl. HQ): 4,400
Japan (1,122) & Korea: 1,249
Latin America: 1,933
North America (US 6,087 & Canada 301): 6,388
(includes all Novo Nordisk and NNE employees in the respective locations)
26,930 million Danish kroner
Sales by business segment
Diabetes and obesity care total:
21,838 million Danish kroner
4,322 million Danish kroner
Sales by region
North America Operations:
13,366 million Danish kroner
USA: 12,878 million Danish kroner
13,564 million Danish kroner
Region Europe: 5,233 million Danish kroner
Region AAMEO: 2,899 million Danish kroner
Region China: 3,029 million Danish kroner
Region Japan & Korea: 1,257 million Danish kroner
Region Latin America: 1,146 million Danish kroner
Novo Nordisk A/S
CVR nr. 24 25 67 90